Cite
HARVARD Citation
Tran, H. et al. (n.d.). A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study). British journal of haematology. pp. 243-251. [Online].